Interleukin-1 alpha mediates the growth proliferative effects of transforming growth factor-beta in p21 null MCF-10A human mammary epithelial cells

Oncogene

Volumn 25, Issue 40, 2006, Pages 5561-5569

  Karakas, B ^a   Weeraratna, A ^b   Abukhdeir, A ^a   Blair, B G ^a   Konishi, H ^a   Arena, S ^a,e   Becker, K ^b   Wood III, W ^b   Argani, P ^a   De Marzo, A M ^a   Bachman, K E ^c   Park, B H ^a,d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF TURIN   (Italy)

Author keywords

Breast cancer; IL 1alpha; p21; TGF beta

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; INTERLEUKIN 1; INTERLEUKIN 1 ALPHA; PROTEIN P21; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; BREAST EPITHELIUM; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DACTINOMYCIN; HUMANS; INTERLEUKIN-1; NUCLEIC ACID SYNTHESIS INHIBITORS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SECOND MESSENGER SYSTEMS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 33748421080     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209540     Document Type: Article

References (23)

1. Bachman KE, Park BH. (2005). Curr Opin Oncol 17: 49-54.
2. Bachman KE, Blair BG, Brenner K, Bardelli A, Arena S, Zhou S et al. (2004). Cancer Biol Ther 3: 221-225.
3. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M et al. (2000). Nature 406: 536-540.
4. Cayrol C, Knibiehler M, Ducommun B. (1998). Oncogene 16: 311-320.
5. Chen CR, Kang Y, Massague J. (2001). Proc Natl Acad Sci USA 98: 992-999.
6. Chou JL, Fan Z, DeBlasio T, Koff A, Rosen N, Mendelsohn J. (1999). Breast Cancer Res Treat 55: 267-283.
7. Cordenonsi M, Dupont S, Maretto S, Insinga A, Imbriano C, Piccolo S. (2003). Cell 113: 301-314.
8. Derynck R, Akhurst RJ, Balmain A. (2001). Nat Genet 29: 117-129.
9. Grille SJ, Bellacosa A, Upson J, Klein-Szanto AJ, van Roy F, Lee-Kwon W et al. (2003). Cancer Res 63: 2172-2178.
10. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E et al. (1996). Science 271: 350-353.
11. Iavarone A, Massague J. (1997). Nature 387: 417-422.
12. Islam S, Kim JB, Trendel J, Wheelock MJ, Johnson KR. (2000). J Cell Biochem 78: 141-150.
13. Kloen P, Jennings CL, Gebhardt MC, Springfield DS, Mankin HJ. (1994a). Int J Cancer 58: 440-445.
14. Kloen P, Jennings CL, Gebhardt MC, Springfield DS, Mankin HJ. (1994b). Eur J Cancer 30A: 678-682.
15. Lei X, Bandyopadhyay A, Le T, Sun L. (2002). Oncogene 21: 7514-7523.
16. Luo Y, Hurwitz J, Massague J. (1995). Nature 375: 159-161.
17. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J et al. (1995). Science 268: 1336-1338.
18. Seoane J, Le HV, Shen L, Anderson SA, Massague J. (2004). Cell 117: 211-223.
19. Siegel PM, Massague J. (2003). Nat Rev Cancer 3: 807-821.
20. Theocharis SE, Margeli AP, Klijanienko JT, Kouraklis GP. (2004). Histopathology 45: 103-118.
21. Turner M, Chantry D, Buchan G, Barrett K, Feldmann M. (1989). J Immunol 143: 3556-3561.
22. Wakefield LM, Winokur TS, Hollands RS, Christopherson K, Levinson AD, Sporn MB. (1990). J Clin Invest 86: 1976-1984.
23. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R et al. (1999). J Clin Invest 103: 197-206.